ALTERNATING 2'-DCF AND RECOMBINANT LEUKOCYTE INTERFERON ALPHA IN HCL
盐酸中的交替 2-DCF 和重组白细胞干扰素 α
基本信息
- 批准号:2464504
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
We administered dCF and IFN-alpha sequentially to pts. with HCL in an
attempt to improve the response rate and duration observed in earlier
studies using each drug alone. In this study, we evaluated pts. for
response by performing bilateral iliac crest bone marrow biopsies and
aspirates since the peripheral blood normalizes rapidly after either
IFN-alpha or dCF treatment but disease becomes patchy in the bone marrow
and might be missed if only unilateral bone marrow biopsies had been
performed. Other studies using IFN-alpha or dCF alone used unilateral
marrow examinations in evaluating response. Using these more relaxed
criteria of response, authors had published high rates of complete
remission to dCF. Of 15 pts. entered in our study, 14 are evaluable for
response with 1 pt. having diffuse osteosclerosis not being evaluable for
marrow response. All pts. had rapid normalization of peripheral blood
counts and all 14 marrow-evaluable pts. were found to have very small
numbers (less than 5% of total marrow cellularity) of residual hairy cells
at the completion of tx. Among the 14 evaluable pts., 4 pts. have
developed progressive disease off tx. The single nonevaluable pt. with
diffuse osteosclerosis developed anemia with increasing sIL-2R levels
consistent with progressive hairy cell leuk- emia. 3 pts. received tx.
With 2-chlorodeoxyadenosine and 1 received IFN-alpha. Although the
initial response rate to the combination of dCF and IFN appears to be no
better than that observed with dCF alone, the response duration may be
longer. The remaining pts. continue to be followed for determination of
response duration.
我们依次给患者使用dCF和ifn - α。在an中加入HCL
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
J E JANIK其他文献
J E JANIK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('J E JANIK', 18)}}的其他基金
PHASE II EFFICACY STUDY OF ROFERON A IN HAIRY CELL LEUKEMIA
Roferon A 治疗毛细胞白血病的 II 期疗效研究
- 批准号:
2464506 - 财政年份:
- 资助金额:
-- - 项目类别:
RGM-CSF AND HIGH DOSE CARBOPLATIN THERAPY IN REFRACTORY OVARIAN CANCER
RGM-CSF 和高剂量卡铂治疗难治性卵巢癌
- 批准号:
3874539 - 财政年份:
- 资助金额:
-- - 项目类别:
PHASE IB TRIAL OF LEVAMISOLE ALONE AND IN COMBINATION WITH R-INTERFERON GAMMA
单独使用左旋咪唑以及与 R-干扰素 GAMMA 联用的 IB 期试验
- 批准号:
2464513 - 财政年份:
- 资助金额:
-- - 项目类别:
PHASE II EVALUATION OF TOPOTECAN IN MELANOMA AND RENAL CELL CARCINOMA
拓扑替康在黑色素瘤和肾细胞癌中的 II 期评估
- 批准号:
3752507 - 财政年份:
- 资助金额:
-- - 项目类别:
PHASE II EFFICACY STUDY OF ROFERON A (R022-8181/002) IN HAIRY CELL LEUKEMIA
ROFERON A (R022-8181/002) 治疗毛细胞白血病的 II 期疗效研究
- 批准号:
3752481 - 财政年份:
- 资助金额:
-- - 项目类别:
POLY ICLC AND ALPHA INTERFERON IN REFRACTORY MALIGNANCY
POLY ICLC 和 α 干扰素治疗难治性恶性肿瘤
- 批准号:
3838223 - 财政年份:
- 资助金额:
-- - 项目类别:
PHASE 1 EVALUATION OF INTRATUMORAL INTERLEUKIN-1 ALPHA
瘤内 INTERLEUKIN-1 ALPHA 的第一阶段评估
- 批准号:
3853339 - 财政年份:
- 资助金额:
-- - 项目类别:
PHASE I EVALUATION OF A MODIFIED HEPATIC ARTERY INFUSION CATHETER
改良肝动脉输注导管的 I 期评估
- 批准号:
3752508 - 财政年份:
- 资助金额:
-- - 项目类别:
PHASE 1 EVALUATION OF INTRATUMORAL INTERLEUKIN-1 ALPHA
瘤内 INTERLEUKIN-1 ALPHA 的第一阶段评估
- 批准号:
3838227 - 财政年份:
- 资助金额:
-- - 项目类别: